Tectonic (TECX) Q2 R&D Soars 142%
Tectonic Therapeutic (NASDAQ:TECX), a biotechnology company advancing a new generation of biologic medicines for hard-to-treat diseases, reported its second quarter 2025 results on August 7, 2025. The headline news was a net loss (GAAP) of $20.0 million in Q2 2025, with a loss per share of $(1.07) (GAAP), wider than analysts’ expectations of $(0.98) (GAAP). reflecting the ramp-up of clinical trials for its lead programs. Despite the higher loss, cash and cash equivalents totaled $287.4 million as of June 30, 2025. Overall, the period was marked by steady pipeline progress but rising costs.
Source: Analyst estimates for the quarter provided by FactSet.
Tectonic Therapeutic develops biologic drugs targeting G protein-coupled receptors (GPCRs), a large family of membrane proteins involved in many diseases. Its proprietary technology, GEODe™, is designed to enable the discovery of GPCR-targeted biologic medicines. The company’s lead asset is TX45, a fusion protein therapy aimed at treating pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF).
Source Fool.com
